Gilead Sciences said it held its annual meeting of stockholders on May 7, 2025, and 1,121,336,290 of the 1,246,634,469 shares of common stock entitled to vote were represented at the start of the meeting, in person or by proxy, which constituted a quorum.

1. 01

   Gilead Sciences said it held its annual meeting of stockholders on May 7, 2025, and 1,121,336,290 of the 1,246,634,469 shares of common stock entitled to vote were represented at the start of the meeting, in person or by proxy, which constituted a quorum.

2. 02

   The company said stockholders elected 9 directors. Daniel P. O’Day received 953,619,782 votes for, 63,040,728 votes against and 4,718,876 abstentions. Broker non-votes for all director nominees were 99,956,982.

3. 03

   The company said stockholders approved the selection of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2025, with 1,041,388,468 votes for and 78,979,344 against. An advisory vote on executive compensation was also approved, with 929,612,739 votes for and 89,351,501 against.

4. 04

   The company said a proposal for an independent Board Chair policy was defeated, with 370,171,536 votes for and 649,612,220 against. A proposal to include the CEO pay ratio factor in executive compensation programs was defeated, with 81,515,333 votes for and 935,564,336 against.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.